These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 32062791)

  • 1. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR).
    Judge DP; Kristen AV; Grogan M; Maurer MS; Falk RH; Hanna M; Gillmore J; Garg P; Vaishnaw AK; Harrop J; Powell C; Karsten V; Zhang X; Sweetser MT; Vest J; Hawkins PN
    Cardiovasc Drugs Ther; 2020 Jun; 34(3):357-370. PubMed ID: 32062791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
    Solomon SD; Adams D; Kristen A; Grogan M; González-Duarte A; Maurer MS; Merlini G; Damy T; Slama MS; Brannagan TH; Dispenzieri A; Berk JL; Shah AM; Garg P; Vaishnaw A; Karsten V; Chen J; Gollob J; Vest J; Suhr O
    Circulation; 2019 Jan; 139(4):431-443. PubMed ID: 30586695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis.
    Zhang X; Goel V; Attarwala H; Sweetser MT; Clausen VA; Robbie GJ
    J Clin Pharmacol; 2020 Jan; 60(1):37-49. PubMed ID: 31322739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
    Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J
    Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
    Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
    Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran.
    Titze-de-Almeida SS; Brandão PRP; Faber I; Titze-de-Almeida R
    Mol Diagn Ther; 2020 Feb; 24(1):49-59. PubMed ID: 31701435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy.
    Benson MD; Dasgupta NR; Rissing SM; Smith J; Feigenbaum H
    Amyloid; 2017 Dec; 24(4):219-225. PubMed ID: 28906150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis.
    Sutherland JE; Hettinger JL; Chan A; Gilbert J; Warner GL; Davis WP
    Nucleic Acid Ther; 2020 Feb; 30(1):33-49. PubMed ID: 31821125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetic-Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis.
    Yu RZ; Collins JW; Hall S; Ackermann EJ; Geary RS; Monia BP; Henry SP; Wang Y
    Nucleic Acid Ther; 2020 Jun; 30(3):153-163. PubMed ID: 32286934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.
    Benson MD; Waddington-Cruz M; Berk JL; Polydefkis M; Dyck PJ; Wang AK; Planté-Bordeneuve V; Barroso FA; Merlini G; Obici L; Scheinberg M; Brannagan TH; Litchy WJ; Whelan C; Drachman BM; Adams D; Heitner SB; Conceição I; Schmidt HH; Vita G; Campistol JM; Gamez J; Gorevic PD; Gane E; Shah AM; Solomon SD; Monia BP; Hughes SG; Kwoh TJ; McEvoy BW; Jung SW; Baker BF; Ackermann EJ; Gertz MA; Coelho T
    N Engl J Med; 2018 Jul; 379(1):22-31. PubMed ID: 29972757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DISCOVERY: prevalence of transthyretin (
    Akinboboye O; Shah K; Warner AL; Damy T; Taylor HA; Gollob J; Powell C; Karsten V; Vest J; Maurer MS
    Amyloid; 2020 Dec; 27(4):223-230. PubMed ID: 32456532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study.
    Minamisawa M; Claggett B; Adams D; Kristen AV; Merlini G; Slama MS; Dispenzieri A; Shah AM; Falk RH; Karsten V; Sweetser MT; Chen J; Riese R; Vest J; Solomon SD
    JAMA Cardiol; 2019 May; 4(5):466-472. PubMed ID: 30878017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
    Adams D; Gonzalez-Duarte A; O'Riordan WD; Yang CC; Ueda M; Kristen AV; Tournev I; Schmidt HH; Coelho T; Berk JL; Lin KP; Vita G; Attarian S; Planté-Bordeneuve V; Mezei MM; Campistol JM; Buades J; Brannagan TH; Kim BJ; Oh J; Parman Y; Sekijima Y; Hawkins PN; Solomon SD; Polydefkis M; Dyck PJ; Gandhi PJ; Goyal S; Chen J; Strahs AL; Nochur SV; Sweetser MT; Garg PP; Vaishnaw AK; Gollob JA; Suhr OB
    N Engl J Med; 2018 Jul; 379(1):11-21. PubMed ID: 29972753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
    Benbrahim M; Norman K; Sanchorawala V; Siddiqi OK; Hughes D
    J Cardiovasc Pharmacol; 2021 May; 77(5):544-548. PubMed ID: 33657048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.
    Nie T; Heo YA; Shirley M
    Drugs; 2023 Oct; 83(15):1425-1432. PubMed ID: 37728865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Therapeutics for Transthyretin Amyloid Cardiomyopathy.
    Campbell CM; Baiyee CAMT; Almaani S; Bumma N; Sharma N; LoRusso S; Redder E; Bittengle J; Pfund K; Friemer M; Tong M; Kahwash R; Efebera Y; Parikh S; Vallakati A
    Am J Ther; 2023 Sep-Oct 01; 30(5):e447-e453. PubMed ID: 37713689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients.
    Moshe-Lilie O; Dimitrova D; Heitner SB; Brannagan TH; Zivkovic S; Hanna M; Masri A; Polydefkis M; Berk JL; Gertz MA; Karam C
    Amyloid; 2020 Dec; 27(4):250-253. PubMed ID: 32578459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patisiran, an RNAi therapeutic for hereditary transthyretin-mediated amyloidosis: Sub-analysis in Taiwanese patients from the APOLLO study.
    Lin KP; Yang CC; Lee YC; Lee MJ; Vest J; Sweetser MT; White MT; Badri P; Hsieh ST; Chao CC
    J Formos Med Assoc; 2024 Sep; 123(9):975-984. PubMed ID: 38548524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demyelinating Neuropathy in a Patient Treated With Revusiran for Transthyretin (Thr60Ala) Amyloidosis.
    Zanazzi G; Arshad M; Maurer MS; Brannagan TH; Tanji K
    J Clin Neuromuscul Dis; 2019 Mar; 20(3):120-128. PubMed ID: 30801482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence, Incidence, and Impact on Mortality of Conduction System Disease in Transthyretin Cardiac Amyloidosis.
    Donnellan E; Wazni OM; Saliba WI; Hanna M; Kanj M; Patel DR; Wilner B; Kochar A; Jaber WA
    Am J Cardiol; 2020 Aug; 128():140-146. PubMed ID: 32650908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.